NCT02486445View on ClinicalTrials.gov

Rivaroxaban for Scheduled Work-up of DVT - The Ri-Schedule Study

PHASE3CompletedINTERVENTIONAL
Enrollment

625

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

November 30, 2018

Study Completion Date

December 30, 2018

Conditions
Deep Venous Thrombosis
Interventions
DRUG

Rivaroxaban

Rivaroxaban 15 mg every 12 hours until the completion of the diagnostic work-up, which should not exceed 24 hours (maximum 2 tablets)

Trial Locations (1)

1606

Ostfold Hospital Trust, Fredrikstad

All Listed Sponsors
lead

Ostfold Hospital Trust

OTHER

NCT02486445 - Rivaroxaban for Scheduled Work-up of DVT - The Ri-Schedule Study | Biotech Hunter | Biotech Hunter